Lime Global is a UK-based company dedicated to becoming the most customer-focused provider of health cover. Lime argues that conventional health insurance is too expensive and overly complicated. It intends to make health insurance affordable allowing customers to buy the top-ups they want without consulting advisers or filling long questionnaires. Lime Global claims to provide customers with a cancer cover providing a lump sum and support following diagnosis, access to 'Rapid Diagnostics' to avail private diagnostic tests, and an online platform where customers and employers can book and pay for clinical services. Lime Global aspires to become a contender in the UK private healthcare market set to grow more than £8 billion. The company points out that it has secured 5 star Trustpilot reviews over the last year with zero complaints to date. They intend to use the investment to support their expansion into Small and Medium Enterprises (SMEs), mental health modules and e-pharmacies, scale customer acquisition, and support the next stage of its growth in late 2021 and early 2022.
/* OVERVIEW */ ?>
Lime Global Rating Review
Pitch rating powered by CROWDRATING™
Rated on 06/08/2021
Log in to view target
£24,077,044
pre-money valuation
1.63%
equity available
209
investors
£2,272
pledge per investor
09666467
company number
Active
company status
01/07/2015
incorporated 9 years
Previous Funding rounds
25 Apr 24 | Seedrs | £474,838 / 119% | 44.33% |
Officers
Peter Anthony VALAITIS
Appointed: 22-09-2016
Peter Anthony VALAITIS
Appointed: 07-09-2016
Peter Anthony VALAITIS
Appointed: 06-09-2016
Peter Anthony VALAITIS
Appointed: 25-08-2016
Peter Anthony VALAITIS
Appointed: 16-08-2016
Peter Anthony VALAITIS
Appointed: 28-07-2016
Peter Anthony VALAITIS
Appointed: 20-07-2016
Peter Anthony VALAITIS
Appointed: 20-07-2016
Peter Anthony VALAITIS
Appointed: 01-07-2016
Peter Anthony VALAITIS
Appointed: 09-06-2016
Peter Anthony VALAITIS
Appointed: 24-05-2016
Peter Anthony VALAITIS
Appointed: 19-04-2016
Peter Anthony VALAITIS
Appointed: 11-04-2016
Peter Anthony VALAITIS
Appointed: 07-04-2016
Peter Anthony VALAITIS
Appointed: 05-04-2016
Peter Anthony VALAITIS
Appointed: 04-04-2016
Peter Anthony VALAITIS
Appointed: 30-03-2016
Peter Anthony VALAITIS
Appointed: 07-03-2016
Peter Anthony VALAITIS
Appointed: 01-03-2016
Peter Anthony VALAITIS
Appointed: 26-01-2016
Peter Anthony VALAITIS
Appointed: 22-01-2016
Peter Anthony VALAITIS
Appointed: 24-12-2015
Peter Anthony VALAITIS
Appointed: 21-12-2015
Peter Anthony VALAITIS
Appointed: 09-12-2015
Peter Anthony VALAITIS
Appointed: 09-12-2015
Peter Anthony VALAITIS
Appointed: 08-12-2015
Peter Anthony VALAITIS
Appointed: 01-12-2015
Peter Anthony VALAITIS
Appointed: 24-11-2015
Peter Anthony VALAITIS
Appointed: 09-11-2015
Peter Anthony VALAITIS
Appointed: 29-10-2015
Peter Anthony VALAITIS
Appointed: 16-10-2015
Peter Anthony VALAITIS
Appointed: 12-10-2015
Peter Anthony VALAITIS
Appointed: 12-10-2015
Peter Anthony VALAITIS
Appointed: 12-10-2015
Peter Anthony VALAITIS
Appointed: 12-10-2015
News
Valuations in Health and Fitness
Carocell Bio Limited | £6.1M |
PulmoBioMed | £4.0M |
Optimise BP | £474.1K |
What the ratings mean
RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.